We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-29.17%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$186M
AUM Growth
+$106M
Cap. Flow
+$16.2M
Cap. Flow %
8.74%
Top 10 Hldgs %
78.1%
Holding
120
New
32
Increased
25
Reduced
31
Closed
26

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.53%
2 Healthcare 15.08%
3 Technology 1.81%
4 Industrials 0.77%
5 Consumer Discretionary 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRVO icon
26
CervoMed
CRVO
$37M
$865K 0.47%
6,238
-10
-0.2% -$1.61K
BHVN
27
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$828K 0.45%
+19,850
New +$839K
CVM.WS
28
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
$764K 0.41%
855
-537
-39% -$480K
TRAW icon
29
Traws Pharma
TRAW
$8.13M
$682K 0.37%
+2,141
New +$1.84M
CTXR icon
30
Citius Pharmaceuticals
CTXR
$15.4M
$640K 0.34%
+33,817
New +$892K
ORMP icon
31
Oramed Pharmaceuticals
ORMP
$192M
$593K 0.32%
185,800
-168,913
-48% -$563K
SOLO
32
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
$587K 0.32%
288,408
-164,388
-36% -$412K
SHIP icon
33
Seanergy Maritime Holdings
SHIP
$401M
$583K 0.31%
7,563
-2,874
-28% -$267K
TOPS icon
34
TOP Ships
TOPS
$4.45M
$572K 0.31%
+34
New +$1.43M
HURA
35
TuHURA Biosciences
HURA
$129M
$526K 0.28%
+544
New +$1.02M
PHAS
36
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$520K 0.28%
124,788
+41,857
+50% +$334K
AVEO
37
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$498K 0.27%
590
+69
+13% +$513
XBIO icon
38
Xenetic Biosciences
XBIO
$10M
$484K 0.26%
+40,455
New +$1.45M
AMRN
39
Amarin Corp
AMRN
$294M
$470K 0.25%
1,550
-22
-1% -$7.68K
GNPX icon
40
Genprex
GNPX
$2.71M
$462K 0.25%
13
-2
-13% -$84.5K
CYTO
41
DELISTED
Altamira Therapeutics Ltd
CYTO
$461K 0.25%
419
+110
+36% +$122K
SEEL
42
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$451K 0.24%
+128
New +$771K
MBOT icon
43
Microbot Medical
MBOT
$96.7M
$442K 0.24%
83,333
VXRT
44
DELISTED
Vaxart
VXRT
$430K 0.23%
1,197,710
+277,063
+30% +$181K
GNCA
45
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
$429K 0.23%
+1,481
New +$5.06K
VBIV
46
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$413K 0.22%
+29,205
New +$612K
NSPR icon
47
InspireMD
NSPR
$36.1M
$408K 0.22%
20,905
+19,918
+2,018% +$805K
ADXS
48
DELISTED
Advaxis Inc
ADXS
$403K 0.22%
1,521,982
+1,480,260
+3,548% +$1.01M
CNSY
49
Cerenome
CNSY
$16.1M
$389K 0.21%
+303
New +$1.09M
TOVX icon
50
Theriva Biologics
TOVX
$10.3M
$379K 0.2%
3,342
-273
-8% -$33K

Similar funds

Sabby Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sabby Management held 120 positions worth $186M, up 133% from $79.5M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Sabby Management deployed $16.2M of net new capital in Q3 2019, opening 32 new positions and adding to 25 existing holdings. Its largest new stake was Pareteum Corporation: 2,248,578 shares worth $2.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 82% of assets, up from 56% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Odonate Therapeutics, Inc. Common Stock, an estimated $1.35M trimmed.

  • Sabby Management's largest Q3 2019 buy was Pareteum Corporation: 2,248,578 shares worth $2.9M.
  • Sabby Management added most to Advaxis Inc in Q3 2019, an estimated $1.01M increase.
  • Sabby Management's biggest Q3 2019 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $1.35M.
  • Sabby Management fully exited Ampio Pharmaceuticals Inc. in Q3 2019, selling an estimated $2.04M.
  • Sabby Management's ten largest holdings make up 78% of its $186M portfolio in Q3 2019.
  • Sabby Management opened 32 new positions and closed 26 in Q3 2019.
  • Sabby Management's portfolio value rose 133% quarter-over-quarter to $186M.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.